Haben wir schon längst aus den Augen verloren, was wir in der Überlebenszeitanalyse schätzen sollten?

Jan Beyersmann

Institute of Statistics, Ulm University

- Estimands: 'intercurrent' or post-randomization events
- Time-to-event: censor post-randomization events?
- Examples:
 - MACE (and censor 'other death'.)
 - Leukemia: censor allogeneic stem cell transplantation.
 - 'Censoring rules' in RCTs
 - (Clinical Hold)
- Censoring independent, random, non-informative?
- Censoring and causality?

Beyersmann

June 2018 1

Editorial by Brophy: Selling Safety — Lessons from Muregilitazas incidence densities (IDs).

- IP and ID the two major workhorses in safety analyses, differing in the denominator only, but
 - IPs probabilities, but do not account for censoring.
 - ▶ IDs account for censoring, but are no probabilities: 33.37 > 1.
 - (IDs estimate hazards under a constant hazard assumption a restrictive assumption, but not a 'dubious concept'.)

Nissen et al.: Muraglitazar and Adverse Events, JAMA 2005, (antidiabetic drug, not unlike Rosiglitazone)

- Authors use incidence proportions (IPs), but discuss that survival analysis would have been more powerful.
- ► That's not the point: IPs estimate *P*(**observed** AE) < *P*(AE)

Beyersmann

June 2018 2

Why hazards?

- Outcome: Jan's death
- Observation process: the audience is looking at me.
- I'm at risk: alive and under observation.
- Independent censoring: your presence
 - does not scare me too much (which might increase my hazard)
 - does not please me too much (which might decrease my hazard)
- If I die right now,
 - it'll happen with the same hazard as without you looking,
 - you'll observe it.
- So you can estimate my hazard (based on 100 Jans...)



Independent vs. informative censoring

Incidence proportion IP

$$IP = \frac{\#AE}{n} = \frac{\#AE/Population time at risk}{(\#AE + \#Deaths before AE)/Population time at risk}$$

Incidence densities IDs

 $\frac{\# AE}{Population time at risk} \quad \text{and} \quad \frac{\# Deaths before AE}{Population time at risk}$

- AE incidence density censors observed Deaths before AE:
 - independent censoring: allows for estimating AE hazard (under a constant hazard assumption)
 - informative censoring: does not allow for probability statements without competing Deaths before AE incidence density
- **Random censoring**: *T* and *C* independent. Does not hold in common pharmaceutical RCTs.

Major AE-workhorses IP and ID: simplified situation

- No censoring. (For the time being.)
- (Time to 1st) AE or 'death' whatever comes first.
- 'Death' some event that precludes AE occurrence.

$$\frac{AE \text{ Patients}}{n} = \frac{\# \text{ AE}}{n} \to P(AE)$$

$$\frac{\# \text{ AE Patients in } [0, t]}{n} = \frac{\# \text{ AE in } [0, t]}{n} \rightarrow P(\text{AE in } [0, t])$$

► ID is # AE/Population time at risk and

AE/Population time at risk
$$-\#AE_{-IR}$$

Competing risks in a nutshell with competing hazard

Deaths before AE/Population time at risk

June 2018

Event-driven trials

- Toy example: 2 patients put on trial at the same time, stop after 1 observed event.
- The data are not independent (censoring not random):

 $T_1 \wedge T_2$, $\mathbf{1}(T_1 \leq T_2)$ $T_1 \wedge T_2$, $\mathbf{1}(T_2 \leq T_1)$

- General counting process & martingale machinery copes with, e.g., event-driven trials:
 - Independent censoring does not disturb the intensity of a counting process. (A probabilistic concept.)
 - Whether or not this is informative, depends on the target parameter. (A statistical concept.)
- Welcome to Babylon: The literature is a mess this side of counting processes...

Babylonian confusion on censoring

- It is not uncommon to use 'independent censoring' and 'non-informative censoring' interchangeably, e.g., Collet, Modelling Survival Data in Medical Research, CRC 2015, p3.
- E.g., O'Quigley, Proportional Hazards Regression, Springer, 2008, p122:

[...] the assumption of independent censoring, sometimes referred to as non informative censoring, [...]

$$P(T_i > x, C_i > x) = P(T_i > x)P(C_i > x)$$

- But this is random censoring!
- This torpedoes competing risks methodology (needed for MACE, AEs, ...)

Beyersmann

June 2018

Two scans from Kleinbaum and Klein, *Survival Analysis* — A Self-Learning Text, Springer 2012

- Kleinbaum and Klein have yet another suggestion: Independent censoring is random censoring within strata.
- And censoring is non-informative when T provides no information on C. (Somewhat circular. And what is T with MACE or AEs or some other post-randomization event other than all-causes death?)

E.g., more from O'Quigley, *Proportional Hazards Regression*, Springer, 2008, p124, f, on censoring by a competing risk

We will need make some assumptions, most often that of independent censoring [of the competing risk] [...] in order to make progress

- In the counting process world, independent censoring by a competing risk is not an assumption, but a theorem.
- But here it says: We will need to assume that, e.g., time-to-CV-death and time-to-non-CV-death are independent.
- Are they?
- And what is time-to-CV-death if one dies from other causes?
- Not the good concept of 'independent censoring', and time-to-CV-death not a well defined random variable.

Beyersmann

June 2018 10

And now some more circular 'definitions'...

Beyersmann

From Ibrahim et al., *Bayesian Survival Analysis*, Springer 2001, p15

Throughout the book, we will also assume that censoring is noninformative in the sense that inferences do not depend on the censoring process.

So, the assumption is that censoring is such that inference based on censored data is o.k.. From Moore, *Applied Survival Analysis Using R*, Springer 2016, p3

[...] one cause of random censoring is patient dropout. If the dropout occurs truly at random [...]

 So, censoring because of dropout is random censoring provided that dropout is random.

June 2018 13

Beyersmann

June 2018

From Hosmer et al., Applied Survival Analysis, Wiley, 2008, p6

Incomplete observation of a survival time due to the end of the study or follow-up is considered a right censored observation because the process by which subjects entered the study is random at the subject level.

With bold face:

Beyersmann

Incomplete observation of a survival time due to the end of the study or follow-up is considered a right **censored** observation **because** the process by which subjects entered the study is random at the subject level.

Following this argument, a censored observation is randomly censored by definition.

June 2018

Random censoring and causal interpretation of KM

- A causal directed acyclic graph:
 - $T \ge t$ at risk at t- \longrightarrow observed event at t
 - C >
- Estimand P(T > t | do(no censoring)) the survival function of (potential) outcomes in a world w/o censoring.
- Well known for Kaplan-Meier (e.g., Gill 1980)

observed survivors > $t = KM(t) \cdot Censoring-KM(t)$

- Simple example of
 - Inverse Probability of Censoring Weighting (or propensity score for 'censoring treatment')
 - g-computation aka truncated product rule

Beyersmann

A first summary

- Survival and event history analysis
 - based on hazards.
 - does complex event patterns and complex incomplete data mechanisms.
 - is way beyond survival functions and Kaplan-Meier.
- Censoring post-randomization events
 - independent: valid hazard inference.
 - informative: requires competing risks methodology for probability inference.
- Counting process machinery makes this rigorous.
- Alas, the literature this side of counting processes is a nightmare...
- We need to sort this out before moving forward in the estimand debate.
- Now, what about censoring and causality?

June 2018

A common misinterpretation of KM



death before t

Beyersmann

Beyersmann

not the proper causal graph for a post-randomization event like 'other death': there are common causal 'parents'.

- You must not use Kaplan-Meier censoring the other post-randomization event - still a common mistake (Schumacher et al., J Clin Epi 2016).
- Need more complex DAG/multistate model/g-computation (e.g., Aalen et al, 2008).

Some references

- Aalen, Borgan, Gjessing: Survival and Event History Analysis, Springer 2008
- Andersen: Censored data. In *Encyclopedia of Biostatistics*, Wiley, 2005
- Allignol, Beyersmann, Schmoor (2016) Statistical issues in the analysis of adverse events in time-to-event data. *Pharm Stat*, 15(4):297–305.
- Unkel et al. (2018): On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Submitted.

Beyersmann

June 2018 21